T-cell engaging-therapies have transformed the treatment landscape of relapsed and refractory B-cell non-Hodgkin lymphomas by offering highly effective treatments for patients with historically limited therapeutic options. This review focuses on advances in chimeric antigen receptor modified T-cells (CAR T-cells) and bispecific antibodies (BsAb), first providing an overview of each product type, followed by exploring the primary data for currently available products in large B-cell lymphoma, follicular lymphoma, and mantle cell lymphoma. This review also highlights key logistical and sequencing considerations across diseases and product types that can impact clinical decision making.
Subjects:
Immunobiology and Immunotherapy
This content is only available as a PDF.
Copyright © 2024 American Society of Hematology
2024
Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.